



CoreTherm® - continued growing market share in Sweden

The Swedish National Board of Health and Welfare today publishes statistics on surgeries in Sweden in 2020. [1] Of the patients with benign prostate enlargement (BPE/BPH) who received some form of curative treatment (KED) during the year, transurethral microwave therapy (TUMT, KED72) accounted for 14% of the procedures.

The total number of resections and other flow-promoting procedures (KED) for BPE patients in Sweden amounted to 4,107 in 2020, which is a decrease of 23% compared to 2019. A major reason for last year's reduction can almost certainly be explained by the pandemic that led to the postponement of planned care. However, despite increasing older male populations, in Sweden, flow-promoting interventions have decreased sharply over the past 30 years since peaks in the late 1980s when 12-13,000 procedures were performed annually.

Transurethral microwave therapy (TUMT) is the medical terminology for the basic methodology of CoreTherm® Concept, ProstaLund's further developed method for the treatment of benign prostate enlargement. The trend continues, with TUMT accounting for an increasing proportion of BPE procedures carried out. From 8.0% in 2018, 11.7% in 2019 to almost 14% in 2020. 564 CoreTherm treatments were performed in 2020 and, after TURP, is the most common flow-promoting procedure in Sweden.

Johan Wennerholm, CEO ProstaLund, comments: "Although Covid-19 also slowed our progress last year, we have continued to strengthen our position and I am pleased with the more than 500 Swedish men who were, after all, offered and received our treatment. When healthcare returns to normal condition, we stand ready to support Swedish urology to do even more for this patient group with our resource-efficient and rapid treatment. Almost 2,500 men are currently awaiting procedure and among another two hundred thousand men who try to relieve their symptoms with medicines daily, there are certainly many who would like to get a cure with CoreTherm®"

[1] <https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikdatabasen/>

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
22 September 2021 15:00:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

CoreTherm® - continued growing market share in Sweden